Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


19.06.2017

1 Cancer Chemother Pharmacol
1 Clin Cancer Res
1 Eur J Obstet Gynecol Reprod Biol
4 Gynecol Oncol
1 Histopathology
1 Int J Oncol
1 Lancet Oncol
1 Obstet Gynecol
2 PLoS One
1 Tumour Biol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Cancer Chemother Pharmacol

  1. MITTAPALLI RK, Nuthalapati S, Shepherd SP, Xiong H, et al
    Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.
    Cancer Chemother Pharmacol. 2017;79:587-594.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  2. HU Q, Hisamatsu T, Hammerle M, Cho MS, et al
    Role of platelet-derived Tgfbeta1 in the progression of ovarian cancer.
    Clin Cancer Res. 2017 Jun 13. pii: clincanres.3272.2016.
    PubMed     Text format     Abstract available


    Eur J Obstet Gynecol Reprod Biol

  3. YILDIRIM N, Akman L, Acar K, Demir S, et al
    Do tumor-infiltrating lymphocytes really indicate favorable prognosis in epithelial ovarian cancer?
    Eur J Obstet Gynecol Reprod Biol. 2017;215:55-61.
    PubMed     Text format     Abstract available


    Gynecol Oncol


  4. A systematic review of patient values, preferences and expectations for the treatment of recurrent ovarian cancer.
    Gynecol Oncol. 2017 Jun 7. pii: S0090-8258(17)30895.
    PubMed     Text format     Abstract available

  5. BEDNAR EM, Oakley HD, Sun CC, Burke CC, et al
    A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment.
    Gynecol Oncol. 2017 Jun 10. pii: S0090-8258(17)30893.
    PubMed     Text format     Abstract available

  6. GRIMM C, Harter P, Alesina PF, Prader S, et al
    The impact of type and number of bowel resections on anastomotic leakage risk in advanced ovarian cancer surgery.
    Gynecol Oncol. 2017 Jun 10. pii: S0090-8258(17)30936.
    PubMed     Text format     Abstract available

  7. FREY MK, Ellis AE, Koontz LM, Shyne S, et al
    Ovarian cancer survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum.
    Gynecol Oncol. 2017 Jun 8. pii: S0090-8258(17)30885.
    PubMed     Text format     Abstract available


    Histopathology

  8. MCINTYRE JB, Rambau PF, Chan A, Yap S, et al
    Molecular alterations in indolent, aggressive and recurrent ovarian low-grade serous carcinoma.
    Histopathology. 2017;70:347-358.
    PubMed     Text format     Abstract available


    Int J Oncol

  9. ZHOU G, Peng F, Zhong Y, Chen Y, et al
    Rhein suppresses matrix metalloproteinase production by regulating the Rac1/ROS/MAPK/AP-1 pathway in human ovarian carcinoma cells.
    Int J Oncol. 2017 Jan 17. doi: 10.3892/ijo.2017.3853.
    PubMed     Text format     Abstract available


    Lancet Oncol

  10. SWISHER EM, Lin KK, Oza AM, Scott CL, et al
    Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
    Lancet Oncol. 2016 Nov 28. pii: S1470-2045(16)30559.
    PubMed     Text format     Abstract available


    Obstet Gynecol

  11. MATSUO K, Machida H, Shoupe D, Melamed A, et al
    Ovarian Conservation and Overall Survival in Young Women With Early-Stage Low-Grade Endometrial Cancer.
    Obstet Gynecol. 2016.
    PubMed     Text format     Abstract available


    PLoS One

  12. ZHANG W, Su J, Xu H, Yu S, et al
    Dicumarol inhibits PDK1 and targets multiple malignant behaviors of ovarian cancer cells.
    PLoS One. 2017;12:e0179672.
    PubMed     Text format     Abstract available

  13. BJERSAND K, Seidal T, Sundstrom-Poromaa I, Akerud H, et al
    The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer.
    PLoS One. 2017;12:e0179363.
    PubMed     Text format     Abstract available


    Tumour Biol

  14. SADLECKI P, Walentowicz P, Bodnar M, Marszalek A, et al
    Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.
    Tumour Biol. 2017;39:1010428317706230.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: